Natera, Inc. operates as a diagnostics company. The Company provides preconception and prenatal genetic testing services. Natera also offers pre-implantation genetic diagnosis, aneuploidy screening, translocation, and single gene testing services.

Annual Report to Security Holders (Form ARS | Period ending 2024-12-31)

Current Report (Form 8-K | Period ending 2025-03-06)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Natera Inc (NTRA US)

Annual Report to Security Holders (Form ARS | Period ending 2024-12-31)

Current Report (Form 8-K | Period ending 2025-03-06)

Annual Report (Form 10-K | Period ending 2024-12-31)

Current Report (Form 8-K | Period ending 2025-01-12)

Current Report (Form 8-K | Period ending 2024-12-02)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)